{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T04:19:45Z","timestamp":1768537185630,"version":"3.49.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1R21AI148096-01"],"award-info":[{"award-number":["1R21AI148096-01"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Rifamycins are integral part of the combination regimen for treatment of pulmonary <jats:italic>Mycobacterium avium-complex<\/jats:italic> [MAC] infection, but different practitioners prefer different rifamycins. The objective of the study was to compare microbial kill and resistance emergence of rifamycins using principles of pharmacokinetics\/pharmacodynamics. First, we identified rifamycin MICs in 20 MAC isolates from patients followed by concentration-response studies in test-tubes. Next, we examined efficacy and resistance suppression of three doses of each rifamycin in the hollow fiber system model of pulmonary MAC [HFS-MAC], mimicking human like concentration-time profile of the drugs. HFS-MAC units were repetitively sampled for total and drug-resistant MAC burden and for drug concentration measurements. Inhibitory sigmoid E <jats:sub>max<\/jats:sub> model, linear regression, and analysis of variance was used for data analysis. For rifabutin 90% of isolates had MIC \u2264 0.125\u00a0mg\/L while for both rifampin and rifapentine this was \u22642.0\u00a0mg\/L. There was no statistically significant difference (<jats:italic>p<\/jats:italic> &amp;gt; 0.05) in maximal kill and effective concentration mediating 50% of the bacterial kill among three rifamycins in the static concentration experiment. In the HFS-MAC, the bactericidal kill (day 0\u20134) for rifampin was 0.89 (95% Confidence Interval (CI): 0.43\u20131.35), for rifapentine was 1.05 (95% CI: 0.08\u20131.23), and for rifabutin was 0.92 (95% CI: 0.61\u20131.24) log<jats:sub>10<\/jats:sub>\u00a0CFU\/ml, respectively. Rifamycins monotherapy failed after just 4-days of treatment and entire MAC population was drug resistant on day 26 of the study. There was no dose dependent difference in MAC kill or resistance suppression among the three rifamycins tested in the HFS-MAC. Therefore, replacing one rifamycin, due to emergence of drug-resistance, with other may not be beneficial in clinical setting.<\/jats:p>","DOI":"10.3389\/fphar.2021.645264","type":"journal-article","created":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T18:55:32Z","timestamp":1618599332000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Comparison of Rifamycins for Efficacy Against Mycobacterium avium Complex and Resistance Emergence in the Hollow Fiber Model System"],"prefix":"10.3389","volume":"12","author":[{"given":"Gunavanthi D.","family":"Boorgula","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laxmi U. M. R.","family":"Jakkula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tawanda","family":"Gumbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bockgie","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shashikant","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1109\/TAC.1974.1100705","article-title":"A new look at the statistical model identification","volume":"19","author":"Akaike","year":"1974","journal-title":"IEEE Trans. Autom. Control."},{"key":"B2","unstructured":"Mycobutin [Rifabutin] capsule, USP2014"},{"key":"B3","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1093\/clinids\/22.supplement_1.s15","article-title":"The clinical pharmacokinetics of rifabutin","volume":"22","author":"Blaschke","year":"1996","journal-title":"Clin. Infect. Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"A4372","DOI":"10.1164\/ajrccm-conference.2020.201.1_MeetingAbstracts.A4372","article-title":"The novel regimen of rifapentine, tedizolid, and minocycline is potent and could shorten therapy duration for pulmonary Mycobacterium kansasii","volume":"201","author":"Chapagain","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B5","volume-title":"Susceptibility testing of mycobacteria, nocardia spp., and other aerobic actinomycetes. 3rd ed. CLSI Standard M24","year":"2018"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1900250","DOI":"10.1183\/13993003.00250-2019","article-title":"Non-tuberculous mycobacterial pulmonary disease","volume":"54","author":"Cowman","year":"2019","journal-title":"Eur. Respir. J."},{"key":"B7","doi-asserted-by":"publisher","first-page":"433","DOI":"10.2217\/fmb.11.25","article-title":"Pharmacokinetic\/pharmacodynamic-based treatment of disseminated Mycobacterium avium","volume":"6","author":"Deshpande","year":"2011","journal-title":"Future Microbiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1128\/aac.02854-15","article-title":"Azithromycin dose to maximize efficacy and suppress acquired drug resistance in pulmonary Mycobacterium avium disease","volume":"60","author":"Deshpande","year":"","journal-title":"Antimicrob. Agents Chemother."},{"key":"B9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/jac\/dkx306","article-title":"The discovery of ceftazidime\/avibactam as an anti-Mycobacterium avium agent","volume":"72","author":"Deshpande","year":"","journal-title":"J. Antimicrob. Chemother."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1128\/aac.01355-09","article-title":"Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular Mycobacterium avium","volume":"54","author":"Deshpande","year":"","journal-title":"Antimicrob. Agents Chemother."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1128\/aac.01761-09","article-title":"Moxifloxacin pharmacokinetics\/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection","volume":"54","author":"Deshpande","year":"","journal-title":"Antimicrob. Agents Chemother."},{"key":"B12","doi-asserted-by":"publisher","first-page":"4652","DOI":"10.1128\/aac.02985-15","article-title":"Thioridazine as chemotherapy for Mycobacterium avium complex diseases","volume":"60","author":"Deshpande","year":"","journal-title":"Antimicrob. Agents Chemother."},{"key":"B13","doi-asserted-by":"publisher","first-page":"i24","DOI":"10.1093\/jac\/dkx304","article-title":"Linezolid as treatment for pulmonary Mycobacterium avium disease","volume":"72","author":"Deshpande","year":"","journal-title":"J. Antimicrob. Chemother."},{"key":"B14","doi-asserted-by":"publisher","first-page":"i48","DOI":"10.1093\/jac\/dkx307","article-title":"A novel ceftazidime\/avibactam, rifabutin, tedizolid and moxifloxacin (CARTM) regimen for pulmonary Mycobacterium avium disease","volume":"72","author":"Deshpande","year":"","journal-title":"J. Antimicrob. Chemother."},{"key":"B15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/jac\/dkx305","article-title":"Tedizolid is highly bactericidal in the treatment of pulmonary Mycobacterium avium complex disease","volume":"72","author":"Deshpande","year":"","journal-title":"J. Antimicrob. Chemother."},{"key":"B16","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/clpt.2011.323","article-title":"Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers","volume":"91","author":"Dooley","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"4904","DOI":"10.1128\/aac.01730-13","article-title":"Protein binding of rifapentine and its 25-desacetyl metabolite in patients with pulmonary tuberculosis","volume":"58","author":"Egelund","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"B18","doi-asserted-by":"publisher","first-page":"34924","DOI":"10.1016\/j.chest.2020.10.031","article-title":"How I Do It: managing M. avium complex lung disease with a little help from my friend","author":"Griffith","year":"2020","journal-title":"Chest"},{"key":"B19","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/qco.0b013e328055d9a2","article-title":"Therapy of nontuberculous mycobacterial disease","volume":"20","author":"Griffith","year":"2007","journal-title":"Curr. Opin. Infect Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1128\/aac.01533-06","article-title":"Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin","volume":"51","author":"Gumbo","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1001\/jama.1907.25320140022001f","article-title":"The nephelometer:an instrument for estimating the number of bacteria in suspensions used for calculating the opsonic index and for vaccines","author":"Mcfarland","year":"1907","journal-title":"Jama"},{"key":"B22","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/2050-6511-15-61","article-title":"Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV-infected tuberculosis patients on lopinavir\/ritonavir-based antiretroviral therapy","volume":"15","author":"Naiker","year":"2014","journal-title":"BMC Pharmacol. Toxicol."},{"key":"B29","unstructured":"Mycobutin [Rifabutin] capsule, USP2014"},{"key":"B23","doi-asserted-by":"publisher","first-page":"i3","DOI":"10.1093\/jac\/dkx311","article-title":"Meta-analyses and the evidence base for microbial outcomes in the treatment of pulmonary Mycobacterium avium-intracellulare complex disease","volume":"72","author":"Pasipanodya","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"B24","doi-asserted-by":"publisher","first-page":"i20","DOI":"10.1093\/jac\/dkx303","article-title":"Failure of the azithromycin and ethambutol combination regimen in the hollow-fibre system model of pulmonary Mycobacterium avium infection is due to acquired resistance","volume":"72","author":"Srivastava","year":"","journal-title":"J. Antimicrob. Chemother."},{"key":"B25","doi-asserted-by":"publisher","first-page":"i43","DOI":"10.1093\/jac\/dkx308","article-title":"A \u201cshock and awe\u201d thioridazine and moxifloxacin combination-based regimen for pulmonary Mycobacterium avium-intracellulare complex disease","volume":"72","author":"Srivastava","year":"","journal-title":"J. Antimicrob. Chemother."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.2174\/138161211797470192","article-title":"In vitro and in vivo modeling of tuberculosis drugs and its impact on optimization of doses and regimens","volume":"17","author":"Srivastava","year":"2011","journal-title":"Curr. Pharm. Des."},{"key":"B27","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1513\/annalsats.201804-236oc","article-title":"Incidence and prevalence of nontuberculous mycobacterial lung disease in a large U.S. Managed care Health plan, 2008-2015","volume":"17","author":"Winthrop","year":"2020","journal-title":"Ann. ATS"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1093\/cid\/ciy346","article-title":"Intermediate susceptibility dose-dependent breakpoints for high dose rifampin, isoniazid, and pyrazinamide treatment of MDR-TB in programs","volume":"67","author":"Zurr","year":"2016","journal-title":"Clin Infect Dis."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.645264\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T18:55:43Z","timestamp":1618599343000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.645264\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,15]]},"references-count":29,"alternative-id":["10.3389\/fphar.2021.645264"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.645264","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,15]]},"article-number":"645264"}}